NCT03746782

Apixaban + DAPT in Lowering Platelet Reactivity and Thrombin Generation

Investigating Synergistic Effects of Apixaban With Dual Anti-Platelet Therapy (DAPT) in Lowering Platelet Reactivity and Thrombin Generation

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 40 (actual)
• Sponsor: CirQuest Labs, LLC · Academic / Other
• Sex: All
• Age: 18 Years – 74 Years
• Healthy volunteers: Accepted

Summary

Investigating Synergistic Effects of Apixaban with Dual Anti-Platelet Therapy (DAPT) in Lowering Platelet Reactivity and Thrombin Generation

Detailed description

Combination anti-platelet therapies particularly those combining aspirin with a P2Y12 antagonist (DAPT) are regarded as the current standard of care therapy for patients with Acute Coronary Syndrome (ACS). As thrombin potently induces platelet dense granular release and causes secondary adenosine 5'-diphosphate (ADP)-mediated P2Y12 receptor activation, apixaban via inhibition of thrombin generation may exhibit synergistic activity with direct P2Y12 receptor blockers such as clopidogrel or ticagrelor. The results from the study will provide a clearer understanding of how these antithrombotic agents work in combination and how the anti-Xa, apixaban, may reduce the contribution of thrombin and general platelet reactivity when used alone and in combination with antiplatelet agents. This study does NOT involve administration of medication to subjects. Experiments will be performed on donated blood samples from participants.

Conditions

• Acute Coronary Syndrome

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Flow Cytrometry; Thrombin Generation Assay	Apixaban combined with blood specimens (in vitro) of study participants

Timeline

• Start date: 2018-07-10
• Primary completion: 2019-11-08
• Completion: 2019-11-08
• First posted: 2018-11-20
• Last updated: 2020-01-23

Locations

1 site across 1 country: United States